Back to News
Market Impact: 0.34
Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands
Source: marketbeat.com
Corporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Geron expects full-year RYTELO net revenue to reach the mid-to-high end of its prior $230 million-$240 million guidance range. The outlook is supported by continued expansion of the telomerase inhibitor's use in lower-risk myelodysplastic syndromes, reinforcing commercial uptake.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
GERN0.58
More News
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost
- SK Hynix Posts Record Profit Amid AI Rush
- Anthropic's IPO could be 'speculative fiction' or a 'generational moment' — investors are split
- Anthropic Gives Traders a Pure-Play Bet on Frontier AI
- Analysis-Hold or sell? High Treasury yields spur US banks to rethink bond portfolios
- Labubu-maker Pop Mart's shares extend declines as third-quarter sales plunge